Syndesi Therapeutics Company

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
Technology: NeuroTech
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Louvain-la-neuve, Vlaams-Brabant, Belgium
Founded Date: 2018-01-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 5
Total Funding: €17M
Estimated Revenue: Less than $1M
Last Funding Type: Series A

Visit Website
Register and Claim Ownership